Informing Cancer Immunotherapy Decisions

OncoSeer Diagnostics, Inc.

OncoSeer Diagnostics, Inc. (OncoSeer), a collaboration with UT Southwestern Medical Center (UTSW), is developing multimarker blood tests that diagnose and predict immune related adverse events (irAE) in oncology patients undergoing immune checkpoint inhibitor (ICI) therapy.

Technology

The Problem

The Solution

OncoSeer Overview

UNMET CLINICAL NEED

American Cancer Society. Cancer Facts and Figures 2022 Haslam & Prasad. JAMA Network Open 2019;2(5): e192535 Zheng etal.The Oncologist 2021; 26:e2002-2012

Literature Citations

Shaheen Khan , Saad A. Khan, Xin Luo, Farjana J. Fattah, Jessica Saltarski, Yvonne Gloria-McCutchen , Rong Lu, Yang Xie, Quan Li, Edward Wakeland and David E. Gerber

Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events

Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown

David Hsiehchen, MD; Mary K. Watters, MD; Rong Lu, PhD; Yang Xie, PhD; David E. Gerber, MD

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

Toxic effects of conventional chemotherapy and molecularly targeted cancer therapies are generally well defined and occur at predictable points. By contrast, owing to their heterogeneous manifestations, unpredictable timing, and clinical overlap with other conditions, immune-related adverse events (irAE) may be more difficult to diagnose and characterize.

Shaheen Khan, Mitchell S. von Itzstein, Rong Lu, Bonnie L. Bermas, David R. Karp, Saad A. Khan, Farjana J. Fattah, Jason Y. Park, Jessica M. Saltarski, Yvonne GloriaMcCutchen, Yang Xie, QuanZhen Li, Edward K. Wakeland, David E. Gerber

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon

Immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAEs) may affect almost any organ system and occur at any point during therapy. Autoantibody analysis may provide insight into the mechanism, nature, and timing of these events.

Amrit S Gonugunta ,Mitchell S von Itzstein, Hong MuMosley , Farjana Fattah, J David Farrar, Angela Mobely, Sawsan Rashdan, Sunny Lai, Salman F Bhai, Bonnie L Bermas,David Karp, Quan-Zhen Li, Edward K Wakeland, David E Gerber

Humoral and Cellular Correlates of a Novel Immune-Related Adverse Event and its Treatment

While immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, associated toxicities termed immune-related adverse events (irAE) occur in a substantial proportion of patients. These autoimmune events may affect almost any organ system.

Jared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Yang Xie, David E Gerber

T-cell tolerant fraction as a predictor of immune-related adverse events

Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs. 

Mitchell S. von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y. Sheffield, Farjana Fattah, Vinita Popat, Murtaza Ahmed, Jade Homsi, Jonathan E. Dowell, Sawsan Rashdan, Jay Lohrey, Hans J. Hammers, Randall S. Hughes, Tao Wang, Yang Xie, David E. Gerber

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of treatment initiation, thereby providing information prior to efficacy assessment.

Jeffrey M. Stone Co-Founder, CEO & Board Member

MAILING ADDRESS

BioLabs NTX at Pegasus Park
3060 Pegasus Park Drive Building 6
Dallas, Texas 75247

Informing Cancer Immunotherapy Decisions

214-704-5000

jeff@jmscapitalinc.com

Contact Us